Aphria Inc. (TSX: APH) (US OTC: APHQF) announced today that its first shipment of medical cannabis to its Australian-based partner Althea Company Pty Ltd. was received by Althea. The shipment is part of a previously announced agreement between Aphria and Althea, in which Aphria will provide the Australian Company with packaged co-branded cannabis oil and dried flower products for the Australian medical cannabis market. Prior to shipment, the Australian Governments’ Office of Drug Control issued an import certificate and Health Canada issued an export certificate.

“We’re excited that Australian patients in need will now have access to Aphria-branded pharmaceutical-grade, clean and safe medical cannabis through our valuable partnership with Althea,” said Gregg Battersby, Vice-President, Commercial Strategy of Aphria.

Vic Neufeld, CEO of Aphria added, “The Australian market continues to represent a key strategic opportunity for Aphria and our shareholders, and today marks an important step in realizing that opportunity and building our presence around the world.”

This is the first of four shipments Aphria will be making to Althea over the next 12 months, with each successive shipment expected to increase in volume. The initial shipment included a mix of cannabis oil products and dried flower, which Althea is making available for distribution to pharmacies for eligible medical cannabis patients in Australia.

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.